CA2846503A1 - Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy - Google Patents

Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy Download PDF

Info

Publication number
CA2846503A1
CA2846503A1 CA2846503A CA2846503A CA2846503A1 CA 2846503 A1 CA2846503 A1 CA 2846503A1 CA 2846503 A CA2846503 A CA 2846503A CA 2846503 A CA2846503 A CA 2846503A CA 2846503 A1 CA2846503 A1 CA 2846503A1
Authority
CA
Canada
Prior art keywords
dihydro
quinazolin
dioxo
methanesulfonamide
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2846503A
Other languages
English (en)
French (fr)
Inventor
Klaus KUCHER
Donald Johns
George IMBERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2846503A1 publication Critical patent/CA2846503A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2846503A 2011-09-07 2011-09-07 Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy Abandoned CA2846503A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
CA2846503A1 true CA2846503A1 (en) 2013-03-14

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2846503A Abandoned CA2846503A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy

Country Status (10)

Country Link
EP (1) EP2753331A1 (ko)
JP (1) JP2014525474A (ko)
KR (1) KR20140071405A (ko)
CN (1) CN103889427A (ko)
AU (1) AU2011376333A1 (ko)
BR (1) BR112014005210A2 (ko)
CA (1) CA2846503A1 (ko)
IN (1) IN2014DN01791A (ko)
MX (1) MX2014002693A (ko)
WO (1) WO2013036224A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CA2549969A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
EP1677789A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
WO2005044265A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
BRPI0620066A2 (pt) 2005-12-20 2011-11-01 Novartis Ag derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados
AU2010316600A1 (en) * 2009-11-03 2012-05-31 Lupin Limited Modified release formulation of lacosamide

Also Published As

Publication number Publication date
AU2011376333A1 (en) 2014-03-13
JP2014525474A (ja) 2014-09-29
CN103889427A (zh) 2014-06-25
MX2014002693A (es) 2014-06-04
KR20140071405A (ko) 2014-06-11
WO2013036224A1 (en) 2013-03-14
IN2014DN01791A (ko) 2015-05-15
BR112014005210A2 (pt) 2017-03-21
EP2753331A1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
JP6861764B2 (ja) 軸索再生および神経機能を促進するための方法および組成物
TWI353835B (en) Novel methods for identifying improved, non-sedati
US10111889B2 (en) Uses of ganaxolone
Rogawski et al. Preclinical pharmacology of perampanel, a selective non‐competitive AMPA receptor antagonist
EP2161995A1 (en) A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4, 3-b) indoles, its pharmacological compound and application method
CA2674460C (en) 3-substituted-h.2.31-benzotriazinone compound for enhancing glutamatergic synaptic responses
US7226949B2 (en) Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
US20230044710A1 (en) Enantiomers of a2-73, analogues, and sigma agonist activity
KR20170048541A (ko) 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
CA2846503A1 (en) Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy
EA023728B1 (ru) Терапевтическое средство от тревожных расстройств
Herrling et al. D-CPPene (SDZ EAA-494)—a competitive NMDA antagonist: pharmacology and results in humans
JP2005314347A (ja) 疼痛抑制剤
KR20120052341A (ko) 신경 세로이드 리포푸스신증의 치료에 사용하기 위한 1ｈ-퀴나졸린-2,4-디온
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
Hemanthkumar Study of anticonvulsant activity of acetazolamide on albino rats and its influence on anticonvulsant activity of sodium valproate
CN111050800A (zh) 血清素3受体激动剂对疼痛的治疗

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160908